Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer

Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahjehan, Faisal, Kamatham, Saivaishnavi, Ritter, Ashton, Kasi, Pashtoon Murtaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745381/
https://www.ncbi.nlm.nih.gov/pubmed/31534737
http://dx.doi.org/10.1002/ccr3.2333
_version_ 1783451534327021568
author Shahjehan, Faisal
Kamatham, Saivaishnavi
Ritter, Ashton
Kasi, Pashtoon Murtaza
author_facet Shahjehan, Faisal
Kamatham, Saivaishnavi
Ritter, Ashton
Kasi, Pashtoon Murtaza
author_sort Shahjehan, Faisal
collection PubMed
description Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy, after progression postimmunotherapy, has shown a near‐complete response in our patient with metastatic anal cancer. This likely is secondary to the sequence of immunotherapy followed by chemotherapy that is yielding greater than historical responses.
format Online
Article
Text
id pubmed-6745381
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67453812019-09-18 Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer Shahjehan, Faisal Kamatham, Saivaishnavi Ritter, Ashton Kasi, Pashtoon Murtaza Clin Case Rep Case Reports Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy, after progression postimmunotherapy, has shown a near‐complete response in our patient with metastatic anal cancer. This likely is secondary to the sequence of immunotherapy followed by chemotherapy that is yielding greater than historical responses. John Wiley and Sons Inc. 2019-08-06 /pmc/articles/PMC6745381/ /pubmed/31534737 http://dx.doi.org/10.1002/ccr3.2333 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Shahjehan, Faisal
Kamatham, Saivaishnavi
Ritter, Ashton
Kasi, Pashtoon Murtaza
Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title_full Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title_fullStr Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title_full_unstemmed Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title_short Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
title_sort dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745381/
https://www.ncbi.nlm.nih.gov/pubmed/31534737
http://dx.doi.org/10.1002/ccr3.2333
work_keys_str_mv AT shahjehanfaisal dramaticresponsetomodifieddocetaxelcisplatinandfluorouracilchemotherapyafterimmunotherapyinapatientwithrefractorymetastaticanalcancer
AT kamathamsaivaishnavi dramaticresponsetomodifieddocetaxelcisplatinandfluorouracilchemotherapyafterimmunotherapyinapatientwithrefractorymetastaticanalcancer
AT ritterashton dramaticresponsetomodifieddocetaxelcisplatinandfluorouracilchemotherapyafterimmunotherapyinapatientwithrefractorymetastaticanalcancer
AT kasipashtoonmurtaza dramaticresponsetomodifieddocetaxelcisplatinandfluorouracilchemotherapyafterimmunotherapyinapatientwithrefractorymetastaticanalcancer

Ejemplares similares